Kathleen Tregoning - Dec 26, 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role
Title: Chief Corporate Affairs Officer
Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Stock symbol
CERE
Transactions as of
Dec 26, 2023
Transactions value $
$31,658
Form type
4
Date filed
12/28/2023, 04:15 PM
Previous filing
Dec 21, 2023
Next filing
Jan 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Options Exercise $31.7K +3.15K +41.91% $10.05 10.7K Dec 26, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -3.15K -1.22% $0.00 255K Dec 26, 2023 Common Stock 3.15K $10.05 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to this option vested and became exercisable on July 28, 2021, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.

Remarks:

Title: Chief Corporate Affairs Officer